Important Advances in HRpos HER2neg Breast Cancer

CE / CME

Experts Highlight the Most Important Advances in HR+/HER2- Breast Cancer

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: May 13, 2025

Expiration: November 12, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case 1: Woman With Grade 2 IDC and 1 Positive Node



  • 42-yr-old premenopausal woman with right breast grade 2 IDC s/p lumpectomy and SLNB

  • 3.2-cm grade 2 IDC

  • ER 95%, PgR 50%, HER2 1+ by IHC, FISH negative, Ki-67 35%, 1/3 SLN positive for ITCs (pT2pN0i+)

  • BRCA1/2 negative

  • Receives ACT x 6, RT, ready to start endocrine therapy 

Which therapy would you recommend?

2.

In your current practice, how often do you test your patients with HR+/HER2- MBC for ESR1, PIK3CA, AKT1, and PTEN genomic alterations?

3.

Patient Case 3: Recurrent HR+/HER2- MBC



  • A 62-yr-old postmenopausal patient with a history of hyperlipidemia is diagnosed with stage II BC and receives adjuvant ET with anastrozole x 5 yr

    • 3 yr after stopping therapy she develops bone metastases



  • She begins therapy with ribociclib and anastrozole and has 24-mo progression-free interval before finding new liver metastases and progression in bones

  • Genomic testing shows an ESR1 mutation 

In your current practice, which of the following therapies would you recommend for this patient?

4.

Which of the following would you educate colleagues about regarding the safety profile associated with imlunestrant vs exemestane or fulvestrant?